FcεRII/CD23 (C-Term) Rabbit Monoclonal Antibody (RM406)

CD23, also known as FcεRII, is a type II transmembrane glycoprotein and C-type lectin encoded by FCER2 in humans.¹ It is composed of a short N-terminal cytoplasmic domain, a membrane-spanning region, a stalk region, and a large C-terminal globular domain. CD23 is expressed in T and B cells, polymorphonuclear leukocytes, bone marrow stromal cells, follicular dendritic cells, and intestinal epithelial cells. Alternative splicing of FCER2 pre-mRNA produces two isoforms, CD23a and CD23b, which differ by seven amino acids in the N-terminal cytoplasmic domain and exhibit distinct functions, as well as different uptake and recycling patterns. CD23 is the low-affinity receptor for IgE and has roles in the growth and development of normal and leukemic B cells, antimicrobial immunity, and monocyte activation.^1,2 It can also be released from cell surfaces by the metalloprotease ADAM10 as various soluble CD23 proteins (sCD23), all of which bind IgE and have cytokine-like activity.¹ Serum levels of CD23 are increased in patients with chronic lymphocytic leukemia (CLL) or hairy cell leukemia.³ Cayman’s FcεRII/CD23 (C-Term) Rabbit Monoclonal Antibody (RM406) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.

WARNING This product is not for human or veterinary use.

1. Acharya, M., Borland, G., Edkins, A.L., et al. CD23/FcεRII: Molecular multi-tasking. Clin. Exp. Immunol. 162(1), 12-23 (2010).

2. Engeroff, P., and Vogel, M. The role of CD23 in the regulation of allergic responses. Allergy 76(7), 1981-1989 (2020).

3. Gordon, J. CD23: Novel disease marker with a split personality. Clin. Exp. Immunol. 86(3), 356-359 (1991).